Celladon Corporation Receives FDA Fast Track Designation for Its ... PR Newswire (press release) "The positive results of the phase 2 CUPID Trial demonstrated the potential of MYDICAR® to become an important treatment for patients with chronic, advanced heart failure," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp. ... |
